EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®

OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx” or “the Company”, Euronext Growth: EXTX), a clinical-stage precision health company developing the Acoustic Cluster Therapy (ACT®), a proprietary ultrasound-mediated drug delivery platform to enhance the efficacy of therapies across multiple diseases, today announces the award of a research and innovation grant from the Norwegian Research Council (NRC) of NOK 7.4 million for its research-based project “Ultrasound Transducer for Acoustic Cluster Therapy.”

The funding will support the Company’s work with its partner GE Healthcare for the development of a next-generation, bespoke, dual-frequency transducer (ultrasound probe) and a precision navigation system to help guide the ACT® procedure for targeted drug delivery in patients to allow real-time monitoring by medical professionals in the clinical setting.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH